479 results about "Injection solution" patented technology

A pen-type full-automatic precision injection system, comprising: a support table (1), an injection assembly (2), a connecting device (3), a control console (4), and a control switch (5). The control console (4) is arranged on the support table (1), the injection assembly (2) is connected to the control console (4) by means of the connecting device (3), and the control switch (5) can control the injection assembly (2) by means of the control console (4). The injection assembly (2) comprises an auxiliary positioning device (21), a housing (22), a drug storage device (23), a first movement assembly (24), and a second movement assembly (25). The auxiliary positioning device (21) is connected to a left wall of the housing (22). The first movement assembly (24) can drive an outer barrel (231) of the drug storage device (23) to move left and right, an injection needle (232) of the drug storage device (23) can penetrate through the housing (22) and the auxiliary positioning device (21) to pierce the skin of a human body, and the second movement assembly (25) can push a pushing rod (233) of the drug storage device (23) to move to push an injection liquid into the human body. The pen-type full-automatic precision injection system can achieve functions such as automatic injection, adjustment of the injection depth, precise control over the needle piercing depth, precise control over the injection dose, precise control over the injection rate, bubble detection, and pressure detection during injection.

The invention provides a preparation method of an edaravone and dextroborneol injection, the injection comprises edaravone, dextroborneol, propylene glycol and sodium pyrosulfite, in the preparation process, the propylene glycol accounting for 60%-85% of the prescription dosage and water accounting for 5%-25% of the prescription dosage are injected into a liquid preparation tank according to the volume ratio, the mixture is heated to 50-60 DEG C, edaravone is added and stirred to be dissolved, and the edaravone and dextroborneol injection is prepared. The preparation method comprises the following steps: dissolving propylene glycol in the remaining prescription dosage, adding dextroborneol which is dissolved by propylene glycol in the remaining prescription dosage in advance, uniformly stirring, adding water which is close to a constant volume, cooling to 25 DEG C or below, adding sodium pyrosulfite, adjusting the pH value to 4.0-5.0, and fixing the volume to a full volume. According to the preparation method of the edaravone dextroborneol injection, auxiliary materials in a specific proportion are matched with the preparation steps, the problem that raw material medicines are extremely easy to separate out in the preparation process is solved, the requirement of the preparation process for an industrial liquid preparation tank is low, industrial operation is convenient, and the preparation cost is low.

The invention discloses a dexmedetomidine and propofol combined reagent and a combination method, and relates to the technical field of combined use of anesthetic drugs. According to the method, firstly, dexmedetomidine is subjected to intravenous pump injection within 5-15 minutes according to the dosage of 0.5-1.0 mu g / kg, propofol is given within 2 minutes after the dexmedetomidine is subjected to general anesthesia, and the dosage of the propofol can be reduced by 10%-50% compared with that of propofol which is independently used. Through pretreatment of dexmedetomidine, the anesthetic effect of propofol can be enhanced, adverse reactions such as blood pressure drop and respiratory depression can be effectively reduced, and anesthetic safety and controllability are improved. The combined reagent comprises independent containers for respectively loading the dexmedetomidine injection and the propofol emulsion, and can be packaged by adopting a double-cavity pre-filled injector, and sequential injection is realized through a controllable opening mechanism, so that unstable emulsification and titer change caused by physical mixing of medicines are avoided.

An anti-aging injection composition, an anti-aging injection, and use thereof. The anti-aging injection composition contains hyaluronic acid or a salt thereof, glycine, proline, lysine hydrochloride, and leucine, which can synergistically promote the generation of collagen and elastin in the skin, thereby helping to correct skin wrinkles, improve skin elasticity, and enhance skin radiance. The anti-aging injection composition can be used to prepare an anti-aging injection, which has the effect of resisting skin aging.

The invention provides an urapidil hydrochloride injection and a preparation method thereof, and particularly relates to the field of medicines. The urapidil hydrochloride composition comprises the following components in w / v: 0.4-0.6% of urapidil hydrochloride; 9-11% of a stabilizer; 0.03 to 0.05 percent of anhydrous disodium hydrogen phosphate; 0.1-0.3% of sodium dihydrogen phosphate monohydrate, and the balance of water for injection, which is supplemented to 100%. The defects in the prior art are overcome, the cost is saved, meanwhile, the impurity level of the urapidil hydrochloride injection after sterilization is reduced, the liquid medicine temperature is reduced in the liquid preparation and filling processes, meanwhile, the inert gas is filled, the influence of metal ions in a production assembly is greatly reduced, and the production efficiency is improved. The levels of impurities C and D in the finished product after the urapidil hydrochloride injection is sterilized are reduced; the prepared urapidil hydrochloride injection is low in impurity level and high in stability, the quality of the urapidil hydrochloride injection meets the requirements of current laws and regulations, and the urapidil hydrochloride injection is superior to a reference preparation.

The invention provides a method for improving product quality by optimizing a posterior pituitary injection purification process, and belongs to the technical field of medicines. According to the method, glacial acetic acid is adopted as a dissolving medium, and the influence of the concentration of glacial acetic acid, the extraction temperature and the filtering condition on the posterior pituitary injection is investigated, so that visible foreign matters and macromolecular substances are effectively removed, and the potency, the specific activity and the potency ratio of the product are improved. Besides, the method is simple to operate, ensures the stability and curative effect of the product, is suitable for industrial production of the posterior pituitary injection, and has important significance for improving the drug quality and meeting clinical requirements.

The utility model relates to the technical field of flushing and sealing tubes, and provides an automatic medicine injection flushing and sealing tube device capable of adding medicine, the automatic medicine injection flushing and sealing tube device comprises a double-cavity injector, two medicine adding devices and a tube pushing device, the double-cavity injector is provided with two injection cavities, the two injection cavities are used for containing injection liquid, the two medicine adding devices are communicated with the two injection cavities respectively, the two medicine adding devices are used for containing medicine, and the tube pushing device is used for pushing the medicine into the double-cavity injector. The tube pushing device is detachably connected with the double-cavity injector, and the tube pushing device is used for driving the double-cavity injector to perform injection. According to the double-cavity injector, the tube pushing device and the medicine adding devices are arranged, so that the double-cavity injector can be driven by the double-cavity injector to push the tube, automatic tube washing and tube sealing or injection can be achieved, the same or different medicines can be added into the two injection cavities through the two medicine adding devices communicated with the two injection cavities respectively in the using process, and the double-cavity injector is convenient to use. Therefore, the use requirements of medical staff in different scenes can be flexibly met.

The invention provides a vitamin B6 injection and a preparation method thereof, and particularly relates to the field of medicines. Comprising 10 g of vitamin B6, a proper amount of a pH regulator, a proper amount of nitrogen and the balance of water for injection, the volume is fixed to 100 ML, and the pH is 2.0-3.0. The method comprises the following steps: S1, adding 70% of injection water into a liquid preparation tank, controlling the water temperature to be less than 40 DEG C, and filling nitrogen into the liquid preparation tank and a pipeline; s2, weighing the vitamin B6 according to the prescription dosage, putting the vitamin B6 into a liquid preparation tank, and stirring for 30-60 minutes at the temperature of 10-40 DEG C to dissolve the vitamin B6; s3, adding a pH (Potential of Hydrogen) regulator with the concentration of 0.01 mol / L to 1 mol / L into the solution obtained in the S2; adjusting the pH (Potential of Hydrogen) to 2.0 to 2.8; s4, fixing the volume of the solution obtained in S3 to 100% of the total volume, and stirring for 15-30 minutes after fixing the volume; s5, sterilizing and filtering the stirred solution, and filling nitrogen; and S6, sterilizing the filled and sealed sample at 121 DEG C for 12 minutes to finally obtain the vitamin B6 injection product. Degradation of related substances of liquid medicine is reduced by controlling a liquid medicine production process, and the more stable vitamin B6 injection is obtained.

The invention discloses a liquid chromatography method for measuring 5-hydroxymethylfurfural in a calcium gluconate and sodium chloride injection. The method comprises the following steps: measuring the calcium gluconate and sodium chloride injection as a test solution; weighing 5-hydroxymethylfurfural, and adding water to dilute the 5-hydroxymethylfurfural to form a reference solution; carrying out continuous sample introduction on the liquid chromatograph by using the reference substance solution to obtain a system applicability solution chromatogram; when the chromatogram of the applicable solution of the system meets the standard, measuring the test solution and the reference solution, respectively injecting the test solution and the reference solution into a liquid chromatograph, and recording the chromatograms; the content of 5-hydroxymethylfurfural in the calcium gluconate and sodium chloride injection is obtained through a 5-hydroxymethylfurfural content calculation formula. The method has the advantages of strong specificity, high sensitivity, good precision, strong durability and the like, and can quantitatively detect 5-hydroxymethylfurfural in the calcium gluconate and sodium chloride injection, so that the safety of clinical medication of the calcium gluconate and sodium chloride injection is improved.

The utility model discloses a ribavirin injection batching device which comprises a main body tank, a cover plate is arranged at the upper end of the main body tank, a rubber sealing gasket is connected to the lower end of the cover plate through a pipeline, the rubber sealing gasket is arranged in the main body tank, a feeding port is formed in the cover plate and the rubber sealing gasket in a penetrating mode, and the feeding port is communicated with the interior of the main body tank. A flow guide assembly is arranged in the main body tank, a transmission bin is formed in the main body tank, a transmission assembly is arranged in the transmission bin and used in cooperation with the flow guide assembly, and a discharging port and an observation window are fixedly connected to the surface of the main body tank. By means of the design, a complete vertical stirring channel is formed, the solution is effectively mixed, it is ensured that the formula is uniform, and at the moment, the second flow guide fan synchronously runs to assist the solution above to be distributed to the bottom to be redistributed.

The invention discloses a method for simultaneously determining N-sodium laureth sarcosinate and phenol red residues in an injection based on a UPLC-MS / MS (Ultra Performance Liquid Chromatography-Mass Spectrometry / Mass Spectrometry) method. According to the method, on the basis of an ultra-high performance liquid chromatography-tandem triple quadrupole mass spectrometer, a 5mM ammonium acetate solution (containing 10% acetonitrile) is taken as a phase A, a 0.2% acetic acid acetonitrile solution is taken as a phase B, a Waters Acquity UPLCBEH C18 column is selected, ESI is taken as a mass spectrometry detection ion source, and the two process residues in the injection are accurately quantified at the same time in a negative ion scanning and multi-reaction monitoring mode. The method is simple in pretreatment, high in detection sensitivity and good in reproducibility, and can be used for corresponding injection process residue identification and quality control.

This invention belongs to the pharmaceutical field and discloses a rubitetidine pharmaceutical composition, its preparation method, and its application. The pharmaceutical composition includes rubitetidine, an organic acid, and additives, wherein: rubitetidine has crystal forms including crystal form C and / or crystal form D; the additives include a lyophilization protectant or a solution stabilizer; the lyophilization protectant is a saccharide compound and / or its derivative; and the solution stabilizer is an alcohol compound. This invention focuses on rubitetidine crystal form C and rubitetidine crystal form D, and prepares a lyophilized rubitetidine formulation by adding specific organic acids and lyophilization protectants. This formulation exhibits good solubility and stability. Furthermore, by adding specific organic acids and solution stabilizers, a rubitetidine injection solution with similarly good solubility and stability can be prepared without adding lyophilization protectants or using a lyophilization-free process, optimizing the process steps and solving the problems of long production cycles and cumbersome reconstitution operations associated with traditional products.

The invention relates to a dexamethasone sodium phosphate injection and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations. The preparation method comprises the following steps: 1, sequentially adding glycerol, edetate disodium and dexamethasone sodium phosphate into water for injection according to a weight ratio of (20-25): (0.08-0.12): (4-6), mixing and dissolving, and introducing nitrogen until the dissolved oxygen content is less than or equal to 1mg / L to obtain a liquid medicine 1; step 2, adding a pH regulator into the liquid medicine 1 to regulate the pH value to 7.0-8.5 to obtain liquid medicine 2; and step 3, filtering, filling and sealing the liquid medicine 2, and controlling the residual oxygen content to be less than or equal to 5% to obtain the dexamethasone sodium phosphate injection. Wherein the whole preparation process is protected by inert gas. According to the preparation method of the dexamethasone sodium phosphate injection provided by the invention, the prescription composition of an original drug does not need to be changed, and the prepared dexamethasone sodium phosphate injection can be stably stored at room temperature by adjusting a specific pH range, keeping filling of an inactive gas until the dissolved oxygen content is less than or equal to 1mg / L in the whole preparation process and controlling the residual oxygen content to be less than or equal to 5%.

The utility model relates to transfusion bottle technical field discloses a self -discharge formula glucose injection transfusion bottle bottle body, including bottle body and the pendant of fixed on bottle body, bottle body is by bottle body, bottle neck section and bottle mouth section is composed, the inner wall of bottle neck section is fixedly connected with the liquid lifting subassembly, the first envelope is equipped with in the bottle mouth section, the side wall of first envelope is fixedly connected with the support cover, one end of support cover and liquid lifting subassembly is through sliding arrangement. In the utility model, when only a small amount of glucose injection is left in the bottle body, the elasticity of the isolating sleeve makes the contraction sliding sleeve slide upward along the outer wall of the support cover, lifting the liquid level of the glucose injection in the bottle body, greatly reducing the residue of the glucose injection in the bottle body. By setting the protective cover, T-shaped column and the second through hole, the first envelope is protected and further fixed. The protective cover does not need to be removed when the infusion device needle is inserted.

The invention discloses a method for detecting anions in a phlegm-heat-clearing injection, the detection method comprises the following steps: a test solution and a reference solution are taken for detection, the phlegm-heat-clearing injection is composed of scutellaria baicalensis, bear gall powder, cornu gorais, honeysuckle, fructus forsythiae and propylene glycol; chromatographic conditions of the detection are as follows: an anion exchange chromatographic column is adopted, an eluent is an acid aqueous solution, an alkali aqueous solution and / or a buffer salt aqueous solution, the flow velocity is 0.1-2.0 ml / min, the column temperature is 20-40 DEG C, a detector is an electrical conductivity detector, the detection mode is suppression electrical conductivity detection, and the sample size is 10-40 [mu] l; and obtaining the content information of the anions in the phlegm-heat clearing injection according to the detection result. The method disclosed by the invention is simple, convenient, efficient and rapid, and provides a theoretical basis for the quality control of the phlegm-heat clearing injection and the deep research of a pharmacodynamic material basis by detecting the content of the anions.

Stable, injectable pharmaceutical compositions are provided, which are useful as ready-to-dilute (RTD) or ready-to-use (RTU) liquid injectable compositions comprising bendamustine or a pharmaceutically acceptable salt thereof, and which are suitable for intravenous administration. Preferably, solution formulations comprise (a) bendamustine, or pharmaceutically acceptable salts, solvates, or hydrates thereof, (b) at least one pharmaceutically acceptable non-aqueous solvent; (c) optionally, at least one pharmaceutically acceptable excipient, and (d) optionally, a pH adjuster, where the pharmaceutical composition is antioxidant-free, and formulated as a ready-to-dilute or ready-to-use liquid composition suitable for parenteral administration. The invention further relates to methods for manufacturing stable, antioxidant-free injectable solutions of bendamustine.

This invention discloses a carbetocin injection solution and its preparation process. The raw materials for the carbetocin injection solution include at least carbetocin, methionine, disodium edetate, an antibacterial agent, a pH adjuster, and a solvent. The pH of the carbetocin injection solution is 4.0-4.5. The concentration of carbetocin is 50 μg / ml-80 μg / ml, the concentration of methionine is 10 mg / ml-20 mg / ml, the concentration of disodium edetate is 5 mg / ml-10 mg / ml, and the concentration of the antibacterial agent is 2 mg / ml-3 mg / ml. By controlling the concentrations of carbetocin, methionine, disodium edetate, and the antibacterial agent, and simultaneously adjusting the pH of the injection solution to 4.0-4.5, this invention eliminates the need for nitrogen purging during the preparation process, thereby enabling the prepared carbetocin injection solution to exhibit high antioxidant properties and stability, allowing for long-term storage at room temperature.

The invention relates to the technical field of medicines, and provides a nalmefene hydrochloride injection and a preparation method thereof, every 1000 injections comprise the following components in parts by weight: 2.0 g of nalmefene hydrochloride based on nalmefene, 18g of osmotic pressure regulator, 0.05-0.1 g of meglumine, and the balance of water for injection to 2000mL. The preparation method comprises the following steps: S1, adding the osmotic pressure regulator and the meglumine in a prescription dosage into the water for injection which accounts for 90% of the total amount of the prescription dosage, stirring until the osmotic pressure regulator and the meglumine are dissolved, and regulating the pH value to 3.5-4.0 through a hydrochloric acid solution; s2, adding a prescription amount of nalmefene hydrochloride into the solution in the step S1, stirring until the nalmefene hydrochloride is dissolved, and adjusting the pH value to 3.5-3.8; and S3, adding water for injection to the total amount, uniformly stirring, filtering, canning into an ampoule bottle, sterilizing, carrying out lamp detection for leakage detection, and packaging. By adding a small amount of meglumine, the amount of the dinalmefene impurity generated by long-term placement and oxidation of the nalmefene hydrochloride injection can be reduced, adverse reactions possibly caused by a large amount of meglumine are reduced, the content of the dinalmefene impurity is maintained at a low level, and the use safety of the injection is improved.

The present invention belongs to the field of pharmaceutical preparations, and particularly relates to a butorphanol tartrate injection and a preparation method thereof. Each milliliter of the butorphanol tartrate injection comprises: 2 mg of butorphanol tartrate, 0.18 - 2.2 mg of tartaric acid, 2.9 - 3.32 mg of sodium tartrate, 0.01 - 0.5 mg of antioxidant, 6.4 mg of sodium chloride and water for injection, and the pH is 3.0 - 5.0. The butorphanol tartrate injection prepared by the present invention solves the influence of light on the product quality through the synergistic effect of tartaric acid and a specific antioxidant, has good light stability, and at the same time avoids the influence of the leaching of metal ions in the brown glass bottle on the product quality during long-term storage of the product, significantly improves the stability of the product, and thus ensures the effectiveness and safety of the product.

The application relates to a compound cefoperazone and avibactam powder injection and a preparation method thereof. The compound powder injection is obtained by uniformly mixing cefoperazone hydrochloride and avibactam sodium, tabletting and crushing. When the powder injection is prepared into an injection solution, the powder injection is easy to disperse and dissolve, is convenient to use, ensures the content of cefoperazone, is not prone to produce beta-lactamase bacterial drug resistance, and has a good market application prospect.

This invention relates to an isosorbide dinitrate pharmaceutical composition injection and its preparation method. In addition to isosorbide dinitrate, the injection formulation also contains meglumine and glutathione. The preferred specifications are 5ml:5mg and 10ml:10mg. The isosorbide dinitrate injection prepared according to the formulation and process of this invention has the characteristics of high excipient safety, simple process, extremely high quality stability and good safety, which is significantly better than the prior art.

The application belongs to the technical field of biological medicine, and discloses a 50 ppm low-deuterium water injection and a preparation method thereof. The application realizes high-purity preparation of low-deuterium water by accurately controlling the deuterium content and optimizing a purification process, guarantees the safety, stability and drug compatibility of the injection, and enhances the clinical application performance.

The application relates to the technical field of pharmaceutical preparations, and particularly discloses a dyphylline injection and a preparation method thereof. The dyphylline injection provided by the application comprises the following components: hydroxypropyl-beta-cyclodextrin, glycine, dyphylline and water for injection. By adding the hydroxypropyl-beta-cyclodextrin and the glycine into the dyphylline injection, the two components synergistically act, the stability of the dyphylline injection after long-term storage can be obviously improved, the increase of the content of impurities in the injection after long-term storage can be effectively prevented, and thus the quality and the pharmaceutical effect of the dyphylline injection product can be effectively improved.

The invention discloses a tinidazole sodium chloride injection difficult to crystallize at low temperature as well as a preparation method and application of the tinidazole sodium chloride injection. Belongs to the technical field of pharmaceutical preparations. The preparation method of the tinidazole sodium chloride injection is adjusted and improved, the tinidazole at a specific nano level is prepared by performing high-pressure homogenization treatment on the tinidazole, and then the tinidazole is dissolved in a specific solvent to prepare a tinidazole solution. The preparation method comprises the following steps: preparing a tinidazole solution, pretreating the tinidazole solution with a polyvinyl alcohol modified solution, and finally mixing the tinidazole solution with a sodium chloride solution to prepare the tinidazole sodium chloride injection, so that the temperature stability of the injection is effectively improved, and the injection is not easy to crystallize at low temperature; according to the invention, the content of tinidazole in the injection is ensured not to be greatly changed, the number of particles is kept at a certain level, the quality of the product is effectively improved, and the safety is improved.

The application provides a paclitaxel liposome injection and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations. The injection is prepared from the following injection-grade raw and auxiliary materials: paclitaxel, phospholipid, cholesterol, gamma-aminobutyric acid, potassium lactate, a buffer, a freeze-drying protective agent and water for injection. The gamma-aminobutyric acid and the potassium lactate are simultaneously added as the liposome membrane stabilizer, the two synergistically act, the compactness and the stability of the lipid bilayer are significantly enhanced, the paclitaxel encapsulation rate is improved, the drug leakage rate is reduced, and the long-term storage stability of the preparation is improved.

The utility model discloses a single medicine injection liquid's paper support device, both sides of the support mechanism all are provided with first folding section, and the first folding section is 90 degrees bending to the inside of support mechanism, the below of first folding section is provided with second folding section, the second folding section is 90 degrees bending to the inside of support mechanism, the second folding section is located the side away from first folding section and is provided with third folding section, the third folding section is 120 degrees bending to the outside of support mechanism, the top of third folding section is provided with bonding section, the outer surface of bonding section and first folding section are fixed with glue bonding, first folding section, second folding section, third folding section and bonding section are all integrated, and the support mechanism for placing medicine injection liquid bottle takes three layers of corrugated paper as raw material, compared with the traditional material such as plastic bracket, foam, the packaging material cost is reduced greatly, and the corrugated paper is easy to obtain, and the price is low, is favorable to large -scale popularization and application.

The invention discloses a preparation process of a high-stability dipyridamole sodium chloride injection. The preparation process comprises the following steps: S1, weighing raw materials and auxiliary materials: weighing 1g of dipyridamole, 90g of sodium chloride, 10-30g of sodium citrate and 30-70g of propylene glycol; s2, adding water for injection accounting for 70% of the prescription dosage into a liquid preparation tank, then adding sodium chloride, sodium citrate and propylene glycol accounting for the prescription dosage, and completely dissolving in a stirring state; s3, adding a proper amount of a hydrochloric acid solution, adjusting the pH value to 2.5, adding dipyridamole according to the prescription amount, and dissolving dipyridamole in a stirring state; s4, adding a proper amount of a sodium hydroxide solution, adjusting the pH value to 4.0, and fixing the volume to the prescription dosage by using the water for injection; s5, filtering the prepared solution, filling the filtered liquid medicine into a glass bottle, filling nitrogen into the bottle, plugging and capping; s6, sterilizing the filled sample; the stability of the prepared sample is obviously higher than that of a commercially available preparation, DP-II degradation impurities are avoided, obvious advantages are achieved, and the safety risk in the use process of the product can be obviously reduced.

The invention discloses a preparation method of a levosimendan injection, and relates to the field of pharmaceutical preparations, the levosimendan injection is composed of a levosimendan solid preparation composition and a special dilution stabilizer; the solid preparation composition is prepared from active ingredients including levosimendan, povidone, a cosolvent and a stable protection additive, the stable protection additive is selected from one or more of mannitol, trehalose and glycine; the preparation method of the levosimendan injection comprises the following specific steps: firstly, forming a levosimendan povidone compound solution; then adding water for injection and fixing the volume to full dose; and drying to obtain the levosimendan solid preparation. A levosimendan solid preparation is matched with glucose or a sodium chloride solution, the levosimendan injection is obtained after uniform shaking, and the effect of improving the stability of the medicine is achieved by optimizing the adding mode, variety and physical state of the stable protection additive.

This invention relates to the field of pharmaceutical injection technology, specifically to a neostigmine methylsulfate injection and its preparation method. The preparation method of the neostigmine methylsulfate injection of this invention includes the following steps: S1 pretreatment of water for injection, S2 preparation, S3 filtration, S4 filling and sealing, and S5 sterilization. This invention features a simple process, high yield, and low cost. It effectively reduces the generation of impurity I in the neostigmine methylsulfate injection, improves the storage stability of the product, reduces potential medication safety hazards caused by impurities, and ensures drug quality and medication safety.

The invention discloses a preparation method of an intestinal canal filling temperature-sensitive gel injection for gastrointestinal anastomosis guided by an ultrasonic endoscope, and belongs to the technical field of regenerative medicine. According to the specific method, poloxamer, chitosan, polycarbophil, polyvinylpyrrolidone, iohexol and methylene blue are utilized to construct the novel intestinal canal filling temperature-sensitive gel injection. The injection can be injected into the anastomotic intestinal segment of the small intestine by using a conventional nasobiliary drainage tube which is clinically used at present, and the injection becomes viscous immediately under the action of the pH value of the small intestine after injection, so that the injection is inhibited from spreading all around. Meanwhile, the injection is quickly converted into high-strength hydrogel under the action of body temperature, and the hydrogel is adhered to small intestine mucosa to inhibit gel sliding. Therefore, the injection can form a section of gel on a target small intestine section, local immobilization filling and supporting of the target small intestine section are achieved, development can be achieved, the operation difficulty of intestinal tube puncture and stent placement in gastrointestinal anastomosis guided by an ultrasonic endoscope can be greatly reduced, the operation efficiency and the success rate are improved, and the operation cost is reduced. The dosage is less than that of normal saline which is conventionally used clinically, and the effect is better. Moreover, the gel temperature can be reduced by injecting low-temperature normal saline after the operation, so that the gel is thoroughly dissolved into a solution and discharged out of the body, and the phenomenon that the gel remains in the intestinal canal after the operation to cause obstruction is avoided. Therefore, the novel intestinal canal filling temperature-sensitive gel injection has very important clinical practical application value for gastrointestinal anastomosis guided by an ultrasonic endoscope.